Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jack Nyberg"'
Autor:
Paul Dorinsky, Alberto Papi, Fernando J. Martinez, Kimberly Rossman, Christy Cappelletti, Nicola A. Hanania, Jack Nyberg, Antonio Anzueto, Elizabeth A. Duncan
Publikováno v:
ERJ Open Research, Vol 6, Iss 2 (2020)
ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research
article-version (VoR) Version of Record
Inhaled corticosteroid/long-acting β2-agonist combination therapy is a recommended treatment option for patients with chronic obstructive pulmonary disease (COPD) and increased exacerbation risk, particularly those with elevated blood eosinophil lev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad34d47650c4d223fa227592ce4bbc1
http://hdl.handle.net/11392/2419104
http://hdl.handle.net/11392/2419104
Autor:
Jack Nyberg, Paul Dorinsky, Kiernan DeAngelis, Nicola A. Hanania, Klaus F. Rabe, Gary T. Ferguson, Shaila Ballal, Patrick Darken
Publikováno v:
Airway pharmacology and treatment.
Objective: To evaluate pneumonia risk in patients with moderate-to-very severe COPD who received budesonide ICS or non-ICS containing therapies. Methods: Safety population data were pooled from 3 Phase III, randomized, double-blind, parallel-group st
Autor:
Christy Cappelletti, Fernando J. Martinez, Kimberly Rossman, Nicola A. Hanania, Jack Nyberg, Antonio Anzueto, Paul Dorinsky, Alberto Papi, Elizabeth A. Duncan
Publikováno v:
A102. COPD: THERAPY.
Publikováno v:
Pharmaceutical statisticsREFERENCES. 19(5)
The term "intercurrent events" has recently been used to describe events in clinical trials that may complicate the definition and calculation of the treatment effect estimand. This paper focuses on the use of an attributable estimand to address inte
Autor:
Christy Cappelletti, Gary T. Ferguson, Edward Kerwin, Elizabeth A. Duncan, Alberto Papi, Antonio Anzueto, Paul Dorinsky, Jack Nyberg
Publikováno v:
Clinical Problems.
Objective: To assess the efficacy and safety of BFF MDI vs budesonide (BD) MDI, formoterol fumarate dihydrate (FF) MDI and Symbicort® Turbuhaler® (BUD/FORM dry powder inhaler [DPI]) in symptomatic subjects with moderate-to-very severe COPD (NCT0276
Publikováno v:
Allergy and asthma proceedings. 39(5)
This is the first study of the inhaled corticosteroid, budesonide, delivered by metered-dose inhaler (BD MDI) using innovative co-suspension delivery technology in adults with asthma.To characterize the effects of BD delivered by MDI on lung function
Autor:
Edward Kerwin, Paul Dorinsky, Lawrence Sher, Elizabeth A. Duncan, Shahid Siddiqui, Colin Reisner, Andrew Wachtel, Jack Nyberg, Patrick Darken
Publikováno v:
Respiratory medicine. 139
This randomized, double-blind, placebo-controlled, cross-over, Phase II dose-ranging study investigated the efficacy and safety of GP MDI (glycopyrronium administered by metered dose inhaler formulated using co-suspension delivery technology) compare
Autor:
Jack Nyberg, Alberto Papi, Paul Dorinsky, Gary T. Ferguson, Christy Cappelletti, Antonio Anzueto, Edward Kerwin, Elizabeth A. Duncan
Publikováno v:
The European Respiratory Journal
TELOS compared budesonide (BD)/formoterol fumarate dihydrate (FF) metered dose inhaler (BFF MDI), formulated using innovative co-suspension delivery technology that enables consistent aerosol performance, with its monocomponents and budesonide/formot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a92d6ca62ca46b4f54b10895ebd96d0b
http://hdl.handle.net/11392/2393066
http://hdl.handle.net/11392/2393066
Autor:
Janet A, Englund, Emmanuel, Walter, Steven, Black, Mark, Blatter, Jack, Nyberg, Frederick L, Ruben, Michael D, Decker, Kenneth, Zollo
Publikováno v:
Pediatric Infectious Disease Journal. 29:105-110
Background: Infants less than 6 months of age are at high risk for influenza disease and influenza-related complications, but no vaccine is licensed for this population. Methods: A double-blind, randomized, placebo-controlled trial was conducted in 1
Autor:
Emmanuel B, Walter, Janet A, Englund, Mark, Blatter, Jack, Nyberg, Frederick L, Ruben, Michael D, Decker, Keith, Reisinger
Publikováno v:
Pediatric Infectious Disease Journal. 28:1099-1104
Although children less than 6 months of age have the highest risk for hospitalization related to influenza infection, influenza vaccine is not approved for these children.In an open-label, off-season study, healthy 6 to 12 week and 6-month-old childr